Grifols S.A. stock surges on board approval for potential US IPO of biopharma unit

Grifols S.A. (ISIN: ES0171996087) announces evaluation of IPO for its US biopharma business, the largest plasma player in America with nearly 300 centers. This move toward self-sufficiency could unlock value for shareholders amid rising global demand for plasma therapies. US investors gain direct exposure to a vertically integrated powerhouse employing over 14,000.

Grifols S.A. stock reacted positively after the board approved initiating a process to evaluate a potential IPO on the US stock market for a portion of shares in its US biopharma business. This development, announced on March 24, 2026, positions the Spanish plasma giant to potentially separate its dominant American operations, which drive over half of group revenues. For US investors, this opens a pathway to invest directly in the world's largest US plasma collection network without the complexities of foreign listings.

As of: 25.03.2026

Dr. Elena Vasquez, Senior Biotech Equity Analyst: In a plasma market strained by surging demand for immunoglobulins and critical therapies, Grifols' US self-sufficiency play could redefine supply chain resilience for global healthcare.

Board Greenlights US IPO Evaluation for Biopharma Arm

Grifols S.A., listed on the Madrid Stock Exchange (BME) under ticker GRF, confirmed its board has approved exploring an IPO of its US biopharma subsidiary. This unit operates nearly 300 plasma donation centers across 40 US states, major manufacturing facilities in California and North Carolina, and employs more than 14,000 people. The business represents the core of Grifols' plasma-derived products, which account for 85.2% of net sales, with the United States and Canada contributing 56.7% of total revenues.

The IPO process aims to create the first fully self-sufficient US player in plasma therapies, independent of foreign plasma, manufacturing, or supply chains. Grifols has built vertical integration covering plasma collection, manufacturing, logistics, testing, and distribution entirely within the US. This model ensures supply continuity in a sector plagued by long lead times and stringent FDA regulations.

The announcement highlights the unit's scale, operational maturity, and recurring revenues from plasma-derived therapies like immunoglobulins for immunology, infectious diseases, pulmonology, and critical care. Demand for these essential medicines remains strong and predictable, fueled by aging populations and rising prevalence of chronic conditions.

Grifols S.A. stock was last seen on BME at 8.840 EUR, reflecting a modest +0.36% daily gain amid the news. This stability underscores investor confidence in the strategic pivot, even as broader biotech markets navigate volatility.

US Biopharma: A Vertically Integrated Powerhouse

Grifols' US biopharma business stands out for its unmatched infrastructure. With close to 400 global donation centers, the lion's share in North America, Grifols collects plasma at scale to produce life-saving therapies. In the US alone, its 300 centers span 40 states, feeding industrial sites that process plasma into finished products without cross-border dependencies.

This setup addresses key vulnerabilities in the plasma industry. Global supply chains face disruptions from geopolitics, pandemics, and regulatory hurdles. Grifols' domestic model mitigates these risks, producing all marketed therapies onshore and bolstering resilience. The company employs over 14,000 in the US, underscoring its economic footprint and operational depth.

Revenue streams benefit from a mature US healthcare system with favorable reimbursement for plasma products. The business combines steady cash flows with growth levers like efficiency gains, portfolio expansion, and center optimizations. Grifols' global network supports international demand, but the US unit's independence could accelerate value creation.

Founded in 1909 in Barcelona, Grifols has evolved into a leader with 25,258 employees across 30+ countries. Its class A shares trade on BME as part of IBEX-35, while class B shares and ADRs (GRFS) offer US access. The IPO could streamline this structure, focusing the parent on diagnostics (8.9% of sales) and hospital products (3%).

Why the Market Cares Now: Unlocking Hidden Value

The timing of this IPO evaluation aligns with intensifying global plasma shortages. Demand for therapies treating immunodeficiencies, autoimmune diseases, and clotting disorders outpaces supply, with immunoglobulins in particular facing multi-year backlogs. Grifols, as the top US collector, is primed to capitalize.

Separating the US unit via IPO would crystallize its value, often discounted in the consolidated group. Investors have long viewed Grifols' US dominance as underappreciated amid past debt concerns and family ownership dynamics. A US listing could attract biotech specialists, sovereign funds, and healthcare-focused ETFs seeking pure-play exposure.

Grifols' strategy extends self-sufficiency beyond the US. Projects in Egypt and Canada exemplify public-private partnerships to build national plasma ecosystems. These reduce reliance on imports, lower costs, and expand supply amid rising global needs. The US IPO reinforces this blueprint, signaling disciplined capital allocation.

For the Grifols S.A. stock on BME, this catalyst arrives as shares trade at levels implying undervaluation relative to plasma peers. The modest uptick to 8.840 EUR reflects measured optimism, with potential for rerating if IPO talks advance concretely.

US Investor Angle: Direct Access to Plasma Dominance

US investors stand to benefit most from this development. The biopharma unit's full domestic footprint eliminates currency risks, tariff exposures, and foreign regulatory divergences that plague European parent investments. A NASDAQ or NYSE listing would enable seamless inclusion in US portfolios, 401(k)s, and indices like the biotech selectors.

Grifols' US operations already power 56.7% of group sales, with plasma products as the profit engine. Post-IPO, shareholders could hold high-conviction stakes in a business with moats in collection scale, manufacturing expertise, and regulatory compliance. This mirrors successful spin-offs like AbbVie's from Abbott, unlocking billions in market cap.

Moreover, US capital markets offer deeper liquidity and valuation multiples for growth healthcare plays. Grifols' recurring revenues from essential therapies align with defensive biotech mandates, appealing amid economic cycles. For American funds, this trumps ADR discounts or BME trading frictions.

The unit's 14,000+ US jobs and state-spanning presence also foster political goodwill, aiding approvals and expansions. As Washington eyes domestic biotech self-reliance, Grifols' model fits national security priorities for critical medicines.

Strategic Self-Sufficiency in a Supply-Constrained World

Grifols' push for self-sufficiency stems from plasma's unique economics. Unlike small-molecule drugs, plasma therapies require human donations, fractionation processes lasting months, and FDA validations. Disruptions anywhere in the chain halt production, as seen in past shortages.

By ring-fencing US operations, Grifols insulates against Europe-US trade tensions, plasma export bans, or donor fluctuations. Its facilities produce the full spectrum of therapies, from albumin for critical care to factor VIII for hemophilia. This end-to-end control supports margins and scalability.

Globally, Grifols pioneers similar models. In Canada, partnerships build collection and processing; in Egypt, they localize supply for MENA demand. These ventures diversify plasma sources while exporting Grifols' playbook, potentially seeding future spin-offs or joint ventures.

The parent company retains synergies in R&D, diagnostics, and biopharma adjacencies. Post-IPO, Grifols S.A. could deleverage, fund innovation, or acquire complementary assets, enhancing IBEX-35 appeal.

Risks and Open Questions Ahead

While promising, the IPO path carries hurdles. Regulatory filings demand transparency on valuations, pro-forma financials, and governance—areas where Grifols' complex ownership has drawn scrutiny. Timing remains uncertain; market windows for biotech IPOs narrow during rate hikes or recessions.

Execution risks loom in plasma economics. Donor retention hinges on compensation amid competition from CSL, Octapharma, and newcomers. Manufacturing expansions face FDA delays, while pricing pressures from payers could squeeze spreads.

Shareholder dilution or control retention post-IPO warrants watching. Grifols' class A/B structure and family stakes may complicate terms. Broader biotech sentiment, tied to reimbursement reforms or biosimilar threats, could cap upside.

For Grifols S.A. stock on BME, near-term volatility may persist until concrete IPO progress emerges. Long-term, successful execution could drive multi-year rerating.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.